NERVALTA 30 mg (Duloxetine) — 28 Delayed-Release Capsules

Active ingredient: Duloxetine • Strength: 30 mg per capsule • Dosage form: Oral delayed-release capsules

Medical Description

NERVALTA 30 mg contains duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI) used in the treatment of certain mood disorders, anxiety disorders, and chronic pain conditions. It works by increasing the availability of serotonin and norepinephrine in the central nervous system, neurotransmitters involved in mood regulation and the modulation of pain signals.

Duloxetine may help relieve symptoms of depression and anxiety and reduce certain types of chronic neuropathic and musculoskeletal pain. The 30 mg strength may be prescribed as an initial dose, during dose adjustment, or as part of an individualized treatment regimen, depending on the indication and the patient's response.

Indications and Potential Benefits

Duloxetine is approved for the following indications in relevant prescribing information:

• Major depressive disorder: Helps improve depressive symptoms, including persistent low mood and loss of interest.
• Generalized anxiety disorder: Helps reduce excessive worry, tension, and associated anxiety symptoms.
• Diabetic peripheral neuropathic pain: Helps relieve nerve pain associated with diabetes.
• Fibromyalgia: Helps reduce widespread pain and associated symptoms in eligible patients.
• Chronic musculoskeletal pain: May help manage persistent pain associated with certain musculoskeletal conditions.

The approved indications and age restrictions may vary by country and product labeling. The 30 mg strength is not necessarily the full therapeutic dose for every condition.

Mechanism of Action

Duloxetine inhibits the reuptake of serotonin (5-HT) and norepinephrine (NE) in the central nervous system. This increases their availability at nerve synapses and enhances descending pathways that help regulate pain perception. Its effects on serotonin and norepinephrine neurotransmission also contribute to its therapeutic action in depression and anxiety disorders.

Dosage and Administration

• Recommended dose: Depends on the condition being treated, the patient's response, tolerability, and medical history.
• Starting dose: A 30 mg daily dose may be prescribed initially for selected patients or indications before reassessment and possible dose adjustment.
• Administration: Take orally, with or without food, according to the prescribing physician's instructions.
• Capsule handling: Swallow the delayed-release capsule whole. Do not crush or chew it, as this may compromise its delayed-release formulation.
• Discontinuation: Treatment should generally be tapered gradually under medical supervision rather than stopped abruptly, to reduce the risk of withdrawal symptoms.

Do not increase, reduce, or discontinue the dose without consulting the treating physician.

Contraindications and Precautions

NERVALTA should not be used in patients with known hypersensitivity to duloxetine or its ingredients. Important precautions include:

• Liver disease: Avoid use in patients with chronic liver disease or cirrhosis; duloxetine may cause liver injury.
• Severe renal impairment: Generally avoid use when the glomerular filtration rate is below 30 mL/minute.
• Uncontrolled hypertension: Blood pressure should be assessed before treatment and monitored during therapy.
• Bipolar disorder: Screen for a history of mania or hypomania because antidepressants may precipitate manic episodes.
• Seizure disorders: Use cautiously in susceptible patients.
• Pregnancy and breastfeeding: Treatment requires an individualized assessment of potential benefits and risks.

Duloxetine is contraindicated with monoamine oxidase inhibitors (MAOIs) in specified circumstances because of the risk of serious interactions.

Possible Side Effects

Common side effects may include:

• Nausea and dry mouth.
• Constipation or reduced appetite.
• Dizziness or headache.
• Sleepiness, fatigue, or insomnia.
• Increased sweating.
• Sexual dysfunction.

Serious adverse effects requiring medical attention include:

• Serotonin syndrome: Agitation, fever, sweating, tremor, muscle rigidity, or confusion.
• Liver injury: Yellowing of the skin or eyes, dark urine, or persistent upper abdominal pain.
• Abnormal bleeding: Increased risk, particularly when combined with anticoagulants or certain anti-inflammatory medicines.
• Hyponatremia: Low blood sodium, which may cause confusion, weakness, or unsteadiness.
• Worsening mood or suicidal thoughts: Particularly important to monitor when treatment is initiated or the dose is changed.
• Severe allergic reactions: Facial swelling, difficulty breathing, or other signs of a serious reaction.

Seek urgent medical care for severe symptoms or suspected serotonin syndrome.

Drug Interactions

Duloxetine may interact with:

• MAOIs: Risk of serotonin syndrome; concomitant use is contraindicated.
• Other serotonergic medicines: Including SSRIs, SNRIs, tramadol, triptans, and certain other medicines, which may increase serotonin syndrome risk.
• Anticoagulants and NSAIDs: May increase the risk of bleeding.
• CYP1A2 inhibitors: Such as fluvoxamine and ciprofloxacin, which may increase duloxetine exposure.
• CYP2D6 substrates: Duloxetine can affect the metabolism of certain medicines, including some tricyclic antidepressants.
• Alcohol: Heavy alcohol consumption may increase the risk of serious liver injury.

Inform the physician or pharmacist about all prescription medicines, over-the-counter products, and supplements before starting treatment.

Storage

Store according to the manufacturer's instructions on the package leaflet. Keep the capsules in their original packaging, protect them from excessive heat and moisture, and keep them out of the reach of children.

References

The following trusted, non-commercial resources support this medical description.

1. U.S. National Library of Medicine — DailyMed (.gov): Duloxetine Delayed-Release Capsules — Official Prescribing Information — indications, dosage, contraindications, warnings, adverse effects, and drug interactions.
2. MedlinePlus — U.S. National Library of Medicine (.gov): Duloxetine Drug Information — uses, administration, precautions, side effects, and discontinuation guidance.
3. U.S. Food and Drug Administration (.gov): Drug Safety Information — official medication safety information and regulatory resources.

These sources provide general clinical information about duloxetine, not confirmation of the specific registration or approved labeling of NERVALTA 30 mg in Egypt. Verify the local package insert for brand-specific instructions.

Patient Disclaimer

This medical description is provided for educational and informational purposes only. It is not intended to replace professional medical advice, diagnosis, or treatment. NERVALTA 30 mg should be used only as prescribed by a qualified healthcare professional. Do not initiate treatment, change the dose, or discontinue the medicine without medical advice. Seek prompt medical attention for severe adverse effects, worsening mood, or suicidal thoughts. Always read the approved package leaflet and consult your physician or pharmacist regarding the appropriate use of this medicine.